Table 2 Approved small-molecule inhibitors of epigenetic enzymes for cancer treatments
Name | Targeta | Cancer types | Approval time |
|---|---|---|---|
Azacitabine | DNMT | Acute myeloid leukemia (AML); Chronic myelomonocytic leukemia (CMML); Myelodysplastic syndromes (MS) | 2004 |
Decitabine | DNMT | AML; CMML; MS | 2006 |
Vorinostat | HDAC | Cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) | 2006 |
Romidepsin | HDAC | CTCL | 2009 |
Belinostat | HDAC | Relapsed or refractory peripheral T-cell lymphoma (PTCL) | 2014 |
Panobinostat | HDAC | Multiple myeloma (MM) | 2015 |
Chidamide | HDAC | Relapsed/refractory PTCL | 2015 |
Enasidenib | IDH2 | Relapsed or refractory AML | 2017 |
Ivosidenib | IDH1 | Relapsed or refractory AML | 2018 |
Tazemetostat | EZH2 | Epithelioid sarcoma and relapsed or refractory follicular lymphoma | 2020 |